Q1 2022 Results

Best percentage change from baseline (%) Company overview Financial review 2022 priorities Appendix References JDQ443 showed early sign of clinical activity with acceptable safety and tolerability 3 INNOVATION KontRASt-01: Phase 1b/2 study of JDQ443 in advanced, KRAS G12C-mutated solid tumors Best ORR across all doses in NSCLC JDQ443, a novel KRAS G12Ci, demonstrated a competitive safety and efficacy profile in NSCLC 100- 50- 20- 30- $ 60- Starting de 200 ng QO 400 mg QO 200mg BD Dose increase to 200 mg BID ■ ORR of 57% (4/7) at the RD of 200 mg BID ■ ORR of 45% (9/20) across all dose levels ■ No Grade 3 or higher treatment-related AEs at RD JDQ443 achieved high systemic exposure PK/PD modelling predicted sustained, high-level target occupancy at the RD Further development ongoing ☐ KontRASt-01 actively recruiting into SHP2i (TNO155) and anti-PD1 (tislelizumab) combo cohorts ◉ KontRASt-02 Ph3 JDQ443 monotherapy vs docetaxel in NSCLC opening soon Data presented at American Association for Cancer Research ORR Objective response rate RD - Recommended dose BID Orally twice daily 18 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation